Detalhe da pesquisa
1.
Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies.
J Am Soc Mass Spectrom
; 32(7): 1567-1574, 2021 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33415981
2.
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.
Cancers (Basel)
; 12(12)2020 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33321969
3.
Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance.
Viruses
; 11(10)2019 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31546586
4.
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Cancer Immunol Res
; 7(10): 1633-1646, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31431433
5.
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Mol Cancer Ther
; 17(7): 1454-1463, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29654064
6.
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.
Blood Adv
; 1(12): 753-765, 2017 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296719